Active	Status	Sponsor type	Region	Phase	Filter
3 Active 5 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gorman, Grainne
REACH CDM, NCT03692312: Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy	Completed	2/3	56	Europe, Canada, US, RoW	Tideglusib, Placebo	AMO Pharma Limited	Congenital Myotonic Dystrophy	04/23	04/23
NCT05267574 / 2021-003471-34: An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)	Terminated	2/3	155	Europe, Canada, RoW	REN001	Reneo Pharma Ltd	Primary Mitochondrial Myopathy	12/23	01/24
FALCON, NCT05650229 / 2021-002846-33: Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease	Active, not recruiting	2	180	Europe, US	KL1333, Placebo	Abliva AB	Primary Mitochondrial Disease	10/25	12/25
Robson, Lisa
No trials found